[Serum level of the tumor marker CA 125 in ovarian pathology].
article
OA: closed
CC0
AI-generated summary
This study found that serum CA-125 levels are elevated in malignant ovarian disease and ovarian endometriosis but normalize with chemotherapy, indicating its utility in diagnosis and monitoring.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The tumor marker CA-125 is an embryonal glycoprotein detectable in tissues derived from celomatic epithelium. Serum CA-125 was determined by RIA in 66 patients with various ovarian pathologies (16 malignant at stage III-IV and 50 benign). Six patients with ovarian carcinoma were monitored during the first week after surgery and chemotherapy for a total of 150 days of treatment. We observed that CA-125 serum level is consistently above the normal range (greater than 35 U/ml) in all malignant diseases. In benign pathology, levels above the normal were found to be represented almost exclusively by ovarian endometriosis. Furthermore, the results demonstrate that chemotherapy alone is capable of lowering CA-125 serum levels. This tumor marker may be of great advantage in diagnosis and follow-up of ovarian malignancy.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
SciLite annotations
chemicals 1
glycoprotein
Source provenance
- europepmc
- last seen: 2026-08-19T06:08:28.815611+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:09:25.758913+00:00
- scilite
- last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0
· commercial use OK